Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Exempt Offering Notice · D

Lisata Therapeutics, Inc.

LSTANASDAQEQUITYCurrent

Exempt Offering Notice

Filed Oct 2, 2026Accepted Oct 2, 2026, 4:23 PM EDTFiling CIK 320017Accession 0000320017-26-000039
Share

Structured filing — D

primary_doc.xml

Open full document ↗

Issuer

Name
LISATA THERAPEUTICS, INC.
CIK
0000320017
Entity type
Corporation
Jurisdiction
DELAWARE
Phone
908-229-2590
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920
Incorporated more than five years ago
true
Previous EDGAR names
CALADRIUS BIOSCIENCES, INC. · Caladrius Biosciences, Inc. · NeoStem, Inc.

Related person 1

First name
DAVID
Last name
MAZZO
Relationships
Executive Officer · Director
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 2

First name
JAMES
Last name
NISCO
Relationships
Executive Officer
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 3

First name
TARIQ
Last name
IMAM
Relationships
Executive Officer
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 4

First name
GREGORY
Last name
BROWN
Relationships
Director
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 5

First name
HEIDI
Last name
HENSON
Relationships
Director
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 6

First name
CYNTHIA
Last name
FLOWERS
Relationships
Director
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 7

First name
STEVEN
Last name
KLOSK
Relationships
Director
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 8

First name
MOHAMMAD
Last name
AZAB
Relationships
Director
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Related person 9

First name
TED
Last name
LOVE
Relationships
Director
Relationship clarification
[blank]
Street
110 ALLEN ROAD
Street (continued)
SECOND FLOOR
City
BASKING RIDGE
State / country code
NJ
State / country
NEW JERSEY
Postal code
07920

Offering

Industry
Biotechnology
Revenue range
Decline to Disclose
Exemption codes
06b
Amendment
false
First sale date
2026-09-17
Offering lasts more than one year
false
Equity securities
true
Option, warrant or other right to acquire a security
true
Business combination
true
Business combination clarification
[blank]
Minimum investment accepted
0
Total offering amount
351,903,103
Amount sold
351,903,103
Remaining amount
0
Amount clarification
[blank]
Non-accredited investors reported
true
Non-accredited investor count
20
Investors already participating
20

Commissions, fees and proceeds

Sales commissions
2,600,000
Finders’ fees
0
Commission / fee clarification
[blank]
Gross proceeds used
0
Use of proceeds clarification
[blank]

Sales compensation recipient 1

Name
H.C.WAINWRIGHT & CO., LLC
CRD
375
Associated broker-dealer
None
Broker-dealer CRD
None
Foreign solicitation
false
Street
430 PARK AVENUE
Street (continued)
4TH FLOOR
City
NEW YORK
State / country code
NY
State / country
NEW YORK
Postal code
10022
Solicitation jurisdictions
All States

Sales compensation recipient 2

Name
LEERINK PARTNERS LLC
CRD
39011
Associated broker-dealer
None
Broker-dealer CRD
None
Foreign solicitation
false
Street
53 STATE STREET
Street (continued)
40TH FLOOR
City
BOSTON
State / country code
MA
State / country
MASSACHUSETTS
Postal code
02109
Solicitation jurisdictions
All States

Sales compensation recipient 3

Name
LIFESCI CAPITAL
CRD
168404
Associated broker-dealer
None
Broker-dealer CRD
None
Foreign solicitation
false
Street
1700 BROADWAY
Street (continued)
40TH FLOOR
City
NEW YORK
State / country code
NY
State / country
NEW YORK
Postal code
10019
Solicitation jurisdictions
All States

Signature authorization

Authorized representative
false

Signature 1

Issuer
LISATA THERAPEUTICS, INC.
Signer
David Mazzo
Signed
/s/ David Mazzo
Title
CEO
Date
2026-10-02

Company context

Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea Therapeutics, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The Company is also advancing MAR002 for the treatment of acromegaly. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. For more information on the Company, please visit www.lisata.com.

Current securities

Historical securities (2)

Recent company filings

  1. ARS filingOct 19, 2026
  2. DEF 14A filingOct 19, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 14, 2026
  4. PRE 14A filingOct 7, 2026
  5. Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureSep 17, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.